Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Revenue (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Revenue for 6 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • Quarterly Revenue changed N/A to $7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.4 million through Dec 2025, up 53.45% year-over-year, with the annual reading at $15.4 million for FY2025, 53.44% up from the prior year.
  • Revenue for Q4 2025 was $7.0 million at Relay Therapeutics, up from $677000.0 in the prior quarter.
  • The five-year high for Revenue was $25.2 million in Q3 2023, with the low at -$1000.0 in Q4 2023.
  • Average Revenue over 5 years is $3.5 million, with a median of $616500.0 recorded in 2021.
  • The sharpest move saw Revenue soared 28233.33% in 2021, then crashed 100.4% in 2023.
  • Over 5 years, Revenue stood at $567000.0 in 2021, then crashed by 55.38% to $253000.0 in 2022, then plummeted by 100.4% to -$1000.0 in 2023, then skyrocketed by 1000800.0% to $10.0 million in 2024, then plummeted by 30.05% to $7.0 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $7.0 million, $677000.0, and $7.7 million for Q4 2025, Q2 2025, and Q1 2025 respectively.